Industry News

Pharmaceutical Industry News

Patients and caregivers share…

February 26th, 2026|Fierce Pharma|

Patients and caregivers share their perspectives on their clinical trial experiences to help industry with future trial optimization and accessibility.

Less than six months after…

February 26th, 2026|Fierce Pharma|

Less than six months after debuting as the first drug that can target a rare tumor type in patients with non-small cell lung cancer, Boehringer Ingelheim’s Hernexeos has quickly widened its reach into the first-line setting

Following an unexpected delay of…

February 26th, 2026|Fierce Pharma|

Following an unexpected delay of the CDC vaccine panel's February meeting, the Advisory Committee on Immunization Practices (ACIP) has selected dates next month to convene and discuss, among other matters, COVID-19 vaccine safety.

Already on a roll with its…

February 26th, 2026|Fierce Pharma|

Already on a roll with its first-in-class FcRn blocker Vyvgart, argenx has reported successful trial results that could pave the way for the fast-rising blockbuster to reach a new indication—ocular myasthenia gravis.

Sarepta Therapeutics CEO Doug…

February 26th, 2026|Fierce Pharma|

Sarepta Therapeutics CEO Doug Ingram announced Wednesday that he will retire by the end of 2026, citing a “shocking and ironic twist of fate” involving the health of his family.

Viatris’ three-year reorganization…

February 26th, 2026|Fierce Pharma|

Viatris' three-year reorganization will affect staffers in a range of functions including the company's commercial teams, R&D, medical affairs and manufacturing. Besides the layoffs, the drugmaker also reported a fire in India.

GSK’s every-two-month injection…

February 25th, 2026|Fierce Pharma|

GSK's every-two-month injection kept adolescents with HIV virologically suppressed at 96 weeks, GSK's ViiV presented at the recent Conference on Retroviruses and Opportunistic Infections.

The treatment landscape for clear…

February 25th, 2026|Fierce Pharma|

The treatment landscape for clear cell renal cell carcinoma could be due for a shake-up following dual breakthroughs from Merck’s Litespark clinical trial program for Welireg. But one critical factor could hinder these Welireg regimens

AI is now routine in how people…

February 25th, 2026|Fierce Pharma|

AI is now routine in how people search and process information, with users relying on systems interpreting intent and delivering direct responses, especially in healthcare.

After promising to sell off 7% of…

February 25th, 2026|Fierce Pharma|

After promising to sell off 7% of its business back in November, Charles River Laboratories has delivered. The CRO is offloading its entire contract manufacturing operation and some of its European discovery service assets, which

In developing media plans to reach…

February 25th, 2026|Fierce Pharma|

In developing media plans to reach the GLP-1-interested consumer, audio advertising may represent a “blind spot,” according to Anna Clement, director head of industry for SiriusXM Media’s pharma vertical.

When BridgeBio presented its…

February 25th, 2026|Fierce Pharma|

When BridgeBio presented its quarterly report on Tuesday, it laid out expectations on the potential threat of generic pricing pressure on Attruby and provided more evidence of the drug's strong launch, possibly giving investors a

Sanofi has kicked off its…

February 25th, 2026|Fierce Pharma|

Sanofi has kicked off its preparations for the 2026 World Cup by becoming an official backer of Boston’s involvement in the soccer showcase.

Novartis is wasting little time…

February 25th, 2026|Fierce Pharma|

Novartis is wasting little time sketching out the radiopharmaceutical details of its $23 billion U.S. investment push. Shortly after announcing a new manufacturing facility for the class of cancer meds in Florida, the pharma giant

The company unveiled detailed…

February 24th, 2026|Fierce Pharma|

The company unveiled detailed results from its pair of late-stage Artistry trials this week at the Conference on Retroviruses and Opportunistic Infections (CROI) in Denver.

A coalition of 15 states is filing…

February 24th, 2026|Fierce Pharma|

A coalition of 15 states is filing a lawsuit against Robert F. Kennedy Jr. and the Centers for Disease Control and Prevention, challenging their overhaul of the vaccine schedule for children in the U.S.